Kaspar Rufibach - Dept Biostat, Univ Zurich

基本信息

浏览量：67

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 148 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Survival Analysis for AdVerse Events with VarYing Follow-Up Times (SAVVY): Summary of Findings and Assessment of Existing Guidelines

Kaspar Rufibach,Jan Beyersmann,Tim Friede,Claudia Schmoor,Regina Stegherr

TRIALSno. 1 (2024)

引用0浏览0WOS引用

Implementation of Statistical Innovation in a Pharmaceutical Company

Kaspar Rufibach,Marcel Wolbers,Jenny Devenport,Godwin Yung,Chris Harbron,Alun Bedding, Zhiyue Huang,Ray Lin,Herbert Pang,Daniel Sabanes Bove, Jianmei Wang

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2024)

引用0浏览0引用

Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study

Kaspar Rufibach,Regina Stegherr,Claudia Schmoor,Valentine Jehl,Arthur Allignol, Annette Boeckenhoff,Cornelia Dunger-Baldauf,Lewin Eisele,Thomas Kuenzel,Katrin Kupas,Friedhelm Leverkus,Matthias Trampisch,Yumin Zhao,Tim Friede,Jan Beyersmann

STATISTICS IN BIOPHARMACEUTICAL RESEARCHno. 4 (2023): 767-780

引用0浏览0引用

Cancer Clinical Trials beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

STATISTICS IN BIOPHARMACEUTICAL RESEARCHno. 2 (2023): 444-449

引用0浏览0引用

Quantification of Follow‐up Time in Oncology Clinical Trials with a Time‐to‐event Endpoint: Asking the Right Questions

Kaspar Rufibach,Lynda Grinsted,Jiang Li,Hans Jochen Weber,Cheng Zheng,Jiangxiu Zhou

PHARMACEUTICAL STATISTICSno. 4 (2023): 671-691

引用1浏览0引用

Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints

Alexandra Erdmann,Jan Beyersmann,Kaspar Rufibach

arXiv (Cornell University) (2023)

引用0浏览0引用

Modified study designs to expand treatment options in personalised oncology: a multistakeholder view

Christophe Le Tourneau,Fabrice Andre,Aslaug Helland,Linda Mileshkin, Warnyta Minnaard,Anja Schiel,Kjetil Tasken,David M. Thomas,Maria Luisa Veronese,Gonzalo Duran-Pacheco,Lada Leyens,Kaspar Rufibach,Marlene Thomas,Alwin Kraemer

European journal of cancer (Oxford, England : 1990)（2023）

引用0浏览0WOS引用

Estimands and Complex Innovative Designs

Olivier Collignon,Anja Schiel,Carl-Fredrik Burman,Kaspar Rufibach,Martin Posch,Frank Bretz

Clinical pharmacology and therapeuticsno. 6 (2022): 1183-1190

引用7浏览0WOS引用

Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation

Alexei C. Ionan, Miya Paterniti,Devan Mehrotra,John Scott,Bohdana Ratitch,Sylva Collins,Shanti Gomatam,Lei Nie,Kaspar Rufibach,Frank Bretz

Statistics in biopharmaceutical researchno. 3 (2022): 554-559

引用2浏览0引用

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials

Kaspar Rufibach,Regina Stegherr,Claudia Schmoor,Valentine Jehl,Arthur Allignol, Annette Boeckenhoff,Cornelia Dunger-Baldauf,Lewin Eisele, Thomas Künzel,Katrin Kupas,Friedhelm Leverkus,Matthias Trampisch,Yumin Zhao,Tim Friede,Jan Beyersmann

arXiv (Cornell University) (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn